10x Genomics, Inc.
10x Genomics, Inc. (TXG) Revenue
Annual & quarterly revenue history · segment & region breakdown
TXG · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 months10x Genomics, Inc. trailing twelve-month (TTM) revenue is $0.64B, an increase of 5.25% year-over-year from $0.64B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.64B | +$0.03B | +5.25% |
| 2024-12-31 | $0.61B | -$0.01B | -1.28% |
| 2023-12-31 | $0.62B | +$0.10B | +19.81% |
| 2022-12-31 | $0.52B | +$0.03B | +5.28% |
| 2021-12-31 | $0.49B | +$0.19B | +64.13% |
| 2020-12-31 | $0.30B | +$0.05B | +21.53% |
| 2019-12-31 | $0.25B | +$0.10B | +68.06% |
| 2018-12-31 | $0.15B | +$0.08B | +105.83% |
| 2017-12-31 | $0.07B | — | — |
Compare revenue vs peers
Medical - Healthcare Information ServicesCompare TXG revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income 10x Genomics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
10x Genomics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from 10x Genomics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TXG revenue · 5 questionsTXG's trailing twelve-month (TTM) revenue is $0.64B. That is an increase of 5.25% year-over-year from $0.64B in FY2025.
▸ Source: FMP · 10x Genomics, Inc. SEC filings · GAAP · 10x Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026